Example searches

TEVA Teva Pharmaceutical Industries Ltd

In Europe, marketing authorizations for pharmaceutical products may be obtained either through a centralized procedure involving the EMA, a mutual recognition procedure which requires submission of applications in other member states following approval by aso-called reference member state, a decentralized procedure that entails simultaneous submission of applications to chosen member states or occasionally through a local national procedure. During 2018, we continued to register products in the European Union, primarily using the decentralized procedure (simultaneous submission of applications to chosen member states). We continue to use, on occasion, the mutual recognition and centralized procedures.

Company profile

Ticker
TEVA
Exchange
OTC
Website
www.tevapharm.com
CEO
Kåre Schultz
Employees
Incorporated in
Israel
Location
Israel
Fiscal year end
Dec 31
Sector
Health Technology > Pharmaceuticals: Generic
Industry (SEC)
Pharmaceutical Preparations
Pfizer • Allergan • Merck & Co. • Warner Chilcott • Johnson & Johnson • ELI LILLY & Co • Bristol Myers Squibb • AbbVie • Mylan • Celgene ...
Former names
Teva Pharmaceutical Industries Limited
SEC CIK
0000818686
Corporate docs

TEVA stock data

(
)
FINRA relative short interest over last month (20 trading days) ?

Calendar

21 Feb 20
25 Feb 20
31 Dec 20

News

Company financial data Financial data

Chart TEVA financial data
Quarter (USD) Dec 19 Sep 19 Jun 19 Mar 19
Revenue 4.47B 4.09B 4.18B 4.15B
Net income 110M -314M -689M -105M
Diluted EPS 0.1 -0.29 -0.63 -0.1
Net profit margin 2.46% -7.67% -16.50% -2.53%
Operating income 148M -81M -644M 134M
Net change in cash 734M -924M 192M 191M
Cash on hand 1.98B 1.24B 2.17B 1.97B
Cost of revenue 2.03B 2.44B 2.44B 2.44B
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 16.89B 18.27B 22.39B 21.9B
Net income -999M -2.15B -16.27B 329M
Diluted EPS -0.91 -2.35 -16.26 0.07
Net profit margin -5.92% -11.77% -72.66% 1.50%
Operating income -443M -1.64B -17.48B 2.15B
Net change in cash 193M 819M -25M -5.96B
Cash on hand 1.98B 1.78B 963M 988M
Cost of revenue 9.35B 9.98B 11.24B 10.04B

Financial data from company earnings reports

Institutional ownership Q4 2019

TEVA institutional ownership history Ownership history
13F holders
 Current Prev Q Change
Total holders 0 0 NaN%
Opened positions 0 0 NaN%
Closed positions 0 0 NaN%
Increased positions 0 0 NaN%
Reduced positions 0 0 NaN%
13F shares
 Current Prev Q Change
Total value 0 0 –
Total shares 0 0 –
Total puts 0 0 –
Total calls 0 0 –
Total put/call ratio – – –
Largest owners
 Shares Value Change
Largest transactions
 Shares Bought/sold Change
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Teligent • Spectrum Pharmaceuticals • Allergan Finance • ARIAD Pharmaceuticals • Nektar Therapeutics • Neurocrine Biosciences • Acorda Therapeutics • Innoviva • NeuBase Therapeutics • Tercica
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
From filing 10-K 2019 FY

Financial reports

View all
10-K
2019 FY
Annual report
21 Feb 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
2 May 19
10-K
2018 FY
Annual report
19 Feb 19
10-Q
2018 Q3
Quarterly report
1 Nov 18
10-Q
2018 Q2
Quarterly report
2 Aug 18
10-Q
2018 Q1
Quarterly report
3 May 18
10-K
2017 Q4
Annual report
12 Feb 18
20-F
2016 Q4
Annual report (foreign)
15 Feb 17

Current reports

View all
8-K
Results of Operations and Financial Condition
12 Feb 20
8-K
Entry into a Material Definitive Agreement
25 Nov 19
8-K
Departure of Directors or Certain Officers
7 Nov 19
8-K
Results of Operations and Financial Condition
7 Nov 19
8-K
Regulation FD Disclosure
23 Oct 19
8-K
Departure of Directors or Certain Officers
2 Oct 19
8-K
Departure of Directors or Certain Officers
7 Aug 19
8-K
Results of Operations and Financial Condition
7 Aug 19
8-K
Submission of Matters to a Vote of Security Holders
11 Jun 19
8-K
Teva Reports First Quarter 2019 Financial Results
2 May 19

Registration and prospectus

View all
F-6
Registration for ADRs (foreign)
13 Nov 18
424B3
Prospectus supplement
19 Apr 18
S-4
Registration of securities issued in business combination transactions
2 Apr 18
S-3/A
Shelf registration (amended)
28 Mar 18
S-3/A
Shelf registration (amended)
16 Feb 18
S-3
Shelf registration
29 Jan 18
S-8
Registration of securities for employees
7 Sep 17
S-8
Registration of securities for employees
12 Oct 16
S-8
Registration of securities for employees
3 Aug 16
424B5
Prospectus supplement for primary offering
19 Jul 16

Proxies

DEFA14A
Additional proxy soliciting materials
16 Apr 19
DEF 14A
Definitive proxy
16 Apr 19
DEF 14A
Definitive proxy
25 Apr 18
DEFA14A
Additional proxy soliciting materials
25 Apr 18

Other

View all
SD
Conflict minerals disclosure
31 May 19
EFFECT
Notice of effectiveness
4 Dec 18
SD
Conflict minerals disclosure
31 May 18
EFFECT
Notice of effectiveness
19 Apr 18
EFFECT
Notice of effectiveness
19 Apr 18
CORRESP
Correspondence with SEC
16 Apr 18
CORRESP
Correspondence with SEC
16 Apr 18
CORRESP
Correspondence with SEC
16 Apr 18
UPLOAD
Letter from SEC
9 Apr 18
UPLOAD
Letter from SEC
15 Aug 17

Ownership

View all
SC 13G/A
Teva Pharmaceutical Industries LTD
14 Feb 20
SC 13G/A
Teva Pharmaceutical Industries LTD
5 Feb 20
SC 13G
Beneficial ownership report
28 Jan 20
SC 13G
Teva Pharmaceutical Industries LTD
14 Feb 19
SC 13G/A
Teva Pharmaceutical Industries LTD
14 Feb 19
SC 13G/A
Teva Pharmaceutical Industries LTD
28 Jan 19
SC 13G/A
Teva Pharmaceutical Industries LTD
13 Feb 18
SC 13D/A
Teva Pharmaceutical Industries LTD
12 Feb 18
SC 13G
Teva Pharmaceutical Industries LTD
9 Feb 18
SC 13G/A
Teva Pharmaceutical Industries LTD
9 Feb 18

Patents

GRANT
Utility
Compliance monitoring module for a breath-actuated inhaler
25 Feb 20
A compliance monitoring module for a breath-actuated inhaler comprising: a miniature pressure sensor, a sensor port of said sensor being pneumatically coupled to a flow channel through which a user can inhale; a processor configured to: receive a signal originating from a dosing mechanism of the inhaler indicating that medication has been released; receive data from a sensing element of the sensor; and based on said signal from said dosing mechanism and said data from said sensing element, make a determination that inhalation of a breath containing medication through said flow channel complies with one or more predetermined requirements for successful dosing; and a transmitter configured to, responsive to said determination, issue a dosing report.
APP
Utility
Drug Repurposing Hypothesis Generation Using Clinical Drug-Drug Interaction Information
9 Jan 20
Embodiments of the present systems and methods may provide techniques for systematic drug repositioning that fully leverages drug-drug interactions.
APP
Utility
Automatic Generation of User and Non-User Cohorts for The Estimation of Drug's Effect from Longitudinal Observational Data
2 Jan 20
Embodiments of the present systems and methods may provide generation of user and non-user cohorts for the estimation of drug's effect from longitudinal observational data that provide reduction of biases, account for progression of disease over time, and improve statistical significance.
APP
Utility
Use of Rasagiline for the Treatment of Restless Legs Syndrome
5 Dec 19
Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.